Viking Therapeutics Completes Patient Enrollment for VK2735 Clinical Trial
Viking Therapeutics announced the completion of patient enrollment in its Phase 3 VANQUISH-2 clinical trial of subcutaneous VK2735, the company's dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors. VK2735 is being developed in both oral and subcutaneous formulations for the potential treatment of metabolic disorders such as obesity. Concurrently, Viking is conducting the Phase 3 VANQUISH-1 study of subcutaneous VK2735 in patients who have obesity or are overweight. Enrollment in VANQUISH-1 was completed in November 2025. Viking is also evaluating VK2735 in a Phase 1 study evaluating a range of potential maintenance dosing regimens. The objectives of the study are to evaluate the safety, tolerability, and pharmacokinetic profile of VK2735 under these various dosing regimens. Exploratory endpoints are assessing change in body weight from baseline, as well as change in body weight following the transition to maintenance dosing. The company expects to report the results from this study in the third quarter of 2026.
